JP2022504400A5 - - Google Patents
Info
- Publication number
- JP2022504400A5 JP2022504400A5 JP2021518905A JP2021518905A JP2022504400A5 JP 2022504400 A5 JP2022504400 A5 JP 2022504400A5 JP 2021518905 A JP2021518905 A JP 2021518905A JP 2021518905 A JP2021518905 A JP 2021518905A JP 2022504400 A5 JP2022504400 A5 JP 2022504400A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variant
- amino acid
- variant according
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024133817A JP7818850B2 (ja) | 2018-10-08 | 2024-08-09 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
| JP2026015850A JP2026082949A (ja) | 2018-10-08 | 2026-02-03 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742682P | 2018-10-08 | 2018-10-08 | |
| US62/742,682 | 2018-10-08 | ||
| US201862775563P | 2018-12-05 | 2018-12-05 | |
| US62/775,563 | 2018-12-05 | ||
| US201862779104P | 2018-12-13 | 2018-12-13 | |
| US62/779,104 | 2018-12-13 | ||
| US201962808601P | 2019-02-21 | 2019-02-21 | |
| US62/808,601 | 2019-02-21 | ||
| US201962846904P | 2019-05-13 | 2019-05-13 | |
| US62/846,904 | 2019-05-13 | ||
| PCT/US2019/055178 WO2020076817A1 (en) | 2018-10-08 | 2019-10-08 | Engineering of dnase enzymes for manufacturing and therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133817A Division JP7818850B2 (ja) | 2018-10-08 | 2024-08-09 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022504400A JP2022504400A (ja) | 2022-01-13 |
| JP2022504400A5 true JP2022504400A5 (enExample) | 2022-10-14 |
Family
ID=70164727
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518905A Pending JP2022504400A (ja) | 2018-10-08 | 2019-10-08 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
| JP2024133817A Active JP7818850B2 (ja) | 2018-10-08 | 2024-08-09 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
| JP2026015850A Pending JP2026082949A (ja) | 2018-10-08 | 2026-02-03 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133817A Active JP7818850B2 (ja) | 2018-10-08 | 2024-08-09 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
| JP2026015850A Pending JP2026082949A (ja) | 2018-10-08 | 2026-02-03 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US10988746B2 (enExample) |
| EP (1) | EP3864147A4 (enExample) |
| JP (3) | JP2022504400A (enExample) |
| KR (1) | KR20210072790A (enExample) |
| CN (1) | CN112996911A (enExample) |
| AU (2) | AU2019358915B2 (enExample) |
| BR (1) | BR112021006737A2 (enExample) |
| CA (1) | CA3115766A1 (enExample) |
| IL (2) | IL325846A (enExample) |
| MX (1) | MX2021004022A (enExample) |
| SG (1) | SG11202103426XA (enExample) |
| WO (1) | WO2020076817A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3740581A4 (en) | 2018-01-16 | 2021-10-27 | CLS Therapeutics Limited | TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY |
| CN112996911A (zh) * | 2018-10-08 | 2021-06-18 | 纽特雷斯股份有限公司 | 用于制造和疗法的脱氧核糖核酸酶的工程改造 |
| US11352613B2 (en) * | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
| US20230072226A1 (en) * | 2020-02-20 | 2023-03-09 | Neutrolis, Inc. | Basic domain-deleted dnase1-like 3 and uses thereof |
| CA3181572A1 (en) * | 2020-06-08 | 2021-12-16 | Paul STABACH | Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections |
| KR20240004247A (ko) * | 2021-02-17 | 2024-01-11 | 뉴트롤리스 인코포레이티드 | 요법에서 제조 및 사용하기 위해 조작된 dnase 1-유사 2 |
| WO2022246139A1 (en) * | 2021-05-21 | 2022-11-24 | Genkin Dmitry Dmitrievich | Immunomodulation of tumor microenvironment |
| EP4448743A4 (en) * | 2021-12-15 | 2026-01-14 | Univ Texas Tech System | IMPROVEMENT IN THE SERUM HALF-LIFE OF DNASE1L3 |
| US20250179451A1 (en) * | 2022-02-23 | 2025-06-05 | Neutrolis, Inc. | Dnase enzymes engineered for improved stability |
| EP4788836A1 (en) * | 2023-10-06 | 2026-08-12 | Neutrolis, Inc. | Biomarker and precision therapy for inflammatory disease |
| WO2026037276A1 (zh) * | 2024-08-12 | 2026-02-19 | 上海交通大学医学院 | 一种减少线粒体dna泄露的方法 |
| CN120424194A (zh) * | 2025-04-30 | 2025-08-05 | 苏州泓迅生物科技股份有限公司 | 一种重组人源纤连蛋白的制备方法及其应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6656685B2 (en) * | 2001-01-29 | 2003-12-02 | Ventana Medical Systems, Inc. | Hybridization buffers using low molecular weight dextran sulfate and methods for their use |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| AU2003230566A1 (en) * | 2002-02-26 | 2003-09-09 | Southern Illinois University | Therapeutic regulation of deoxyribonuclease-1-like-3 activity |
| EP1440981A3 (en) * | 2003-01-21 | 2005-11-23 | Research Association for Biotechnology | Full-length human cdna |
| US9248166B2 (en) | 2003-07-14 | 2016-02-02 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| RU2269356C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
| WO2006130034A1 (fr) | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| DK2086642T3 (da) | 2006-10-18 | 2014-09-29 | Periness Ltd | Dnase til behandling af subfertilitet hos mænd |
| EP2076592B1 (en) | 2006-10-23 | 2017-04-12 | Medical Research Council | Polymerase |
| US20090010966A1 (en) | 2007-06-21 | 2009-01-08 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
| HUE041426T2 (hu) * | 2009-11-02 | 2019-05-28 | Univ Washington | Terápiás nukleáz-készítmények és eljárások |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| EP2561367A1 (en) | 2010-04-22 | 2013-02-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| US9644197B2 (en) * | 2010-06-04 | 2017-05-09 | Sk Chemicals Co., Ltd. | Fusion protein having factor VII activity |
| US9198957B2 (en) | 2011-01-31 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Treatment and prevention of bacterial vaginosis and Gardnerella vaginalis infections |
| AU2012222833B2 (en) * | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| WO2012122477A1 (en) * | 2011-03-10 | 2012-09-13 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| CA2834626A1 (en) * | 2011-04-29 | 2012-11-01 | University Of Washington | Therapeutic nuclease compositions and methods |
| WO2012166611A2 (en) | 2011-05-27 | 2012-12-06 | Immune Disease Institute, Inc. | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| US8883735B2 (en) * | 2011-11-04 | 2014-11-11 | Novartis Ag | Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs |
| CA2858983C (en) | 2011-12-12 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| GB201208879D0 (en) | 2012-05-21 | 2012-07-04 | London School Hygiene & Tropical Medicine | Therapeutic for treating Clostridium difficile infection |
| US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
| SI3063275T1 (sl) * | 2013-10-31 | 2020-02-28 | Resolve Therapeutics, Llc | Terapevtske fuzije nukleaza-albumin in postopki |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| JP2017527618A (ja) | 2014-09-08 | 2017-09-21 | ゴッサム バイオファーマシューティカルズ，インコーポレイティド | 肺サルコイドーシスの治療方法 |
| US11047855B2 (en) | 2015-03-01 | 2021-06-29 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
| EP3273238A1 (en) | 2016-07-22 | 2018-01-24 | Universitätsklinikum Hamburg-Eppendorf | Immunodiagnostic detection of anti-neutrophil antibodies |
| CN110199015A (zh) | 2016-09-30 | 2019-09-03 | 波赛达治疗公司 | 修饰干细胞记忆t细胞、其制造方法与使用方法 |
| US20190350178A1 (en) * | 2017-01-20 | 2019-11-21 | Universitätsklinikum Hamburg-Eppendorf | Animal model for drug development |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| UA129696C2 (uk) * | 2017-08-18 | 2025-07-09 | Ньютроліс Інк. | СКОНСТРУЙОВАНІ ФЕРМЕНТИ ДНКази ТА ЇХНЄ ЗАСТОСУВАННЯ В ТЕРАПІЇ |
| CN112996911A (zh) * | 2018-10-08 | 2021-06-18 | 纽特雷斯股份有限公司 | 用于制造和疗法的脱氧核糖核酸酶的工程改造 |
| US20220025343A1 (en) * | 2019-02-04 | 2022-01-27 | Neutrolis, Inc. | Engineered human extracellular dnase enzymes for drug candidate selection |
| EA202190940A1 (ru) * | 2019-05-13 | 2021-10-15 | Ньютролис Инк. | РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ |
| KR20240004247A (ko) * | 2021-02-17 | 2024-01-11 | 뉴트롤리스 인코포레이티드 | 요법에서 제조 및 사용하기 위해 조작된 dnase 1-유사 2 |
| AU2023382621A1 (en) * | 2022-11-14 | 2025-06-05 | Neutrolis, Inc. | Dnase 1-like 3 engineered for improved expression and use in therapy |
-
2019
- 2019-10-08 CN CN201980073970.5A patent/CN112996911A/zh active Pending
- 2019-10-08 WO PCT/US2019/055178 patent/WO2020076817A1/en not_active Ceased
- 2019-10-08 BR BR112021006737-0A patent/BR112021006737A2/pt unknown
- 2019-10-08 IL IL325846A patent/IL325846A/en unknown
- 2019-10-08 KR KR1020217013090A patent/KR20210072790A/ko active Pending
- 2019-10-08 SG SG11202103426XA patent/SG11202103426XA/en unknown
- 2019-10-08 AU AU2019358915A patent/AU2019358915B2/en active Active
- 2019-10-08 EP EP19870853.9A patent/EP3864147A4/en active Pending
- 2019-10-08 CA CA3115766A patent/CA3115766A1/en active Pending
- 2019-10-08 JP JP2021518905A patent/JP2022504400A/ja active Pending
- 2019-10-08 MX MX2021004022A patent/MX2021004022A/es unknown
- 2019-10-08 IL IL282058A patent/IL282058B2/en unknown
- 2019-11-27 US US16/697,502 patent/US10988746B2/en active Active
-
2021
- 2021-03-23 US US17/210,129 patent/US11840712B2/en active Active
-
2022
- 2022-02-10 US US17/668,674 patent/US11578314B2/en active Active
-
2023
- 2023-10-30 US US18/497,106 patent/US12565642B2/en active Active
-
2024
- 2024-08-09 JP JP2024133817A patent/JP7818850B2/ja active Active
-
2025
- 2025-12-17 AU AU2025283522A patent/AU2025283522B2/en active Active
-
2026
- 2026-01-30 US US19/465,481 patent/US20260152732A1/en active Pending
- 2026-02-03 JP JP2026015850A patent/JP2026082949A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shao et al. | Advancements of Annexin A1 in inflammation and tumorigenesis | |
| Calvo et al. | Function and evolution of a mosquito salivary protein family | |
| Price et al. | The biochemistry of cancer dissemination | |
| JP5632126B2 (ja) | プロテアーゼ阻害 | |
| US11578314B2 (en) | Engineering of DNASE enzymes for manufacturing and therapy | |
| JP2022500078A5 (enExample) | ||
| US20080227691A1 (en) | Blood Coagulation FVIII Analogues | |
| CA2705541C (en) | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 | |
| AU2013270682A1 (en) | Procoagulant compounds | |
| JP2012512645A5 (enExample) | ||
| WO2008085828A2 (en) | Peptide modulators of angiogenesis and use thereof | |
| Meens et al. | Risky communication in atherosclerosis and thrombus formation | |
| JP2011184453A (ja) | プラスミン阻害療法 | |
| IL316406A (en) | Lipid-modified relaxin B peptide chains and their medical use | |
| Campos et al. | The Kazal-type inhibitors infestins 1 and 4 differ in specificity but are similar in three-dimensional structure | |
| JP2009112314A5 (enExample) | ||
| WO2023072311A1 (zh) | 宽体金线蛭抗凝血因子XIa多肽及其应用 | |
| JP5751519B2 (ja) | 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質 | |
| CN104387474A (zh) | 一种肿瘤血管梗塞剂多肽、基因、表达载体及其应用 | |
| JP2021046437A (ja) | サイトカインストーム抑制剤 | |
| US6906037B2 (en) | Therapeutic peptide-based constructs | |
| TWI638830B (zh) | 附加唾液酸化糖鏈之多肽 | |
| CN108404119B (zh) | Fgf-21类似物的制备及在血栓治疗中的应用 | |
| US20120077733A1 (en) | Antagonists against interaction of pf4 and rantes | |
| JP2009528831A (ja) | キメラＫｕｎｉｔｚドメインおよびその使用 |